» Articles » PMID: 34488288

The Effect of Genistein on Insulin Resistance, Inflammatory Factors, Lipid Profile, and Histopathologic Indices in Rats with Polycystic Ovary Syndrome

Overview
Date 2021 Sep 7
PMID 34488288
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, irregular menstruation, ovulatory dysfunction, and insulin resistance. Recent studies have reported the possible role of phytoestrogens in PCOS. This animal study aimed to evaluate the effects of genistein on insulin resistance, inflammatory factors, lipid profile, and histopathologic indices on PCOS.

Methods: PCOS was induced by 1 mg/kg of letrozole in adult Sprague-Dawley rats. The rats then received normal saline (PCOS group), 150 mg/kg of metformin, or 20 mg/kg of genistein dissolved in 1% methylcellulose solution for 42 days. Body weight, the glycemic and lipid profile, and inflammatory, antioxidative, and histopathological parameters were assessed at the end of the intervention.

Results: Treatment with genistein significantly alleviated the increased level of fasting blood insulin (p=0.16) and the homeostatic model assessment of insulin resistance (p=0.012). In addition, the genistein group had significantly lower levels of serum malondialdehyde (p=0.039) and tumor necrosis factor-alpha (p=0.003), and higher superoxide dismutase enzyme activity (p<0.001). Furthermore, the histopathological analysis indicated that genistein administration led to an increase in luteinization and the development of fewer cysts (p<0.05).

Conclusion: Biochemical and histopathological analyses indicated that genistein administration to rats with PCOS induced significant remission in oxidative, inflammatory, and glycemic and histopathologic parameters.

Citing Articles

Consumption of soya isoflavones improved polycystic ovary syndrome-associated metabolic disorders in a rat model.

Xiao C, Carbonel A, Lima P, Hendry A, Tsang B Br J Nutr. 2024; :1-9.

PMID: 38826091 PMC: 11499085. DOI: 10.1017/S0007114524001296.


Activity of isoflavone in managing polycystic ovary syndrome symptoms (Review).

Raihanah C, Sukrasno S, Kurniati N Biomed Rep. 2024; 20(5):80.

PMID: 38590945 PMC: 10999901. DOI: 10.3892/br.2024.1768.


The Role of Genistein in Mammalian Reproduction.

Guelfi G, Pasquariello R, Anipchenko P, Capaccia C, Pennarossa G, Brevini T Molecules. 2023; 28(21).

PMID: 37959856 PMC: 10647478. DOI: 10.3390/molecules28217436.


Therapeutic Effect of Extracts on Letrozole-Induced Polycystic Ovarian Syndrome and its Complications in Murine Model.

Rani R, Sharma A, Chitme H Clin Med Insights Endocrinol Diabetes. 2023; 16:11795514231203864.

PMID: 37901891 PMC: 10612436. DOI: 10.1177/11795514231203864.


Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds.

Kosmalski M, Frankowski R, Deska K, Rozycka-Kosmalska M, Pietras T Nutrients. 2023; 15(13).

PMID: 37447164 PMC: 10343927. DOI: 10.3390/nu15132838.


References
1.
Zhang T, Chi X . Estrogenic properties of genistein acting on FSHR and LHR in rats with PCOS. Pol J Vet Sci. 2019; 22(1):83-90. DOI: 10.24425/pjvs.2019.127075. View

2.
Henin N, Vincent M, Gruber H, Van den Berghe G . Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J. 1995; 9(7):541-6. DOI: 10.1096/fasebj.9.7.7737463. View

3.
Heim K, Tagliaferro A, Bobilya D . Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem. 2003; 13(10):572-584. DOI: 10.1016/s0955-2863(02)00208-5. View

4.
Fu Z, Gilbert E, Pfeiffer L, Zhang Y, Fu Y, Liu D . Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes. Appl Physiol Nutr Metab. 2012; 37(3):480-8. PMC: 4337421. DOI: 10.1139/h2012-005. View

5.
Ding T, Hardiman P, Petersen I, Wang F, Qu F, Baio G . The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017; 8(56):96351-96358. PMC: 5707105. DOI: 10.18632/oncotarget.19180. View